Medicine and Dentistry
Malignant Neoplasm
84%
Overall Survival
69%
Disease
66%
Castration Resistant Prostate Cancer
55%
Breast Cancer
55%
Prostate Cancer
52%
Clinical Trial
52%
Progression Free Survival
49%
Metastatic Carcinoma
49%
BRCA1
48%
Kidney Metastasis
48%
Sunitinib
47%
Pembrolizumab
47%
Biological Marker
41%
Neoplasm
38%
Recurrent Disease
36%
Adverse Event
35%
Radiation Therapy
34%
Ovarian Cancer
34%
Transitional Cell Carcinoma
33%
Oncology
32%
Immunotherapy
31%
Biochemical Recurrence
29%
Targeted Therapy
27%
Transcriptomics
27%
Cancer Therapy
26%
Hazard Ratio
25%
Clear Cell Renal Cell Carcinoma
24%
Solid Malignant Neoplasm
23%
BRCA2
22%
Personalized Medicine
21%
Computer Assisted Tomography
21%
Prostate Specific Antigen
21%
Antineoplastic Activity
20%
Cancer Risk
20%
Prostate Specific Membrane Antigen
19%
Arm
18%
Lymphocyte
17%
Pancreas Adenocarcinoma
17%
Ascites
15%
Urothelial Cancer
15%
Pancreas Cancer
15%
Niraparib
15%
Antibody Response
15%
Hypofractionated Radiotherapy
15%
Abiraterone Acetate
15%
Cabozantinib
15%
Positron Emission Tomography
15%
Androgen Deprivation Therapy
15%
Cancer Treatment
14%
Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
63%
Overall Survival
61%
Chemotherapy
60%
Breast Cancer Susceptibility Gene 1 (BRCA1)
59%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
58%
Sunitinib
55%
Pembrolizumab
55%
Progression-free Survival
49%
Prostate-specific Antigen
43%
Clinical Trials
41%
Breast Cancer
41%
BRCA2 mutation
37%
Tumor
34%
Response Rate
34%
BRCA mutation Carriers
34%
Phase II Trial
33%
BRCA2
33%
Programmed Death-ligand 1 (PD-L1)
30%
Hazard Ratio
29%
Biochemical Failure
29%
Breast Cancer Risk
28%
Pancreatic Ductal Adenocarcinoma
28%
Ovarian Cancer
26%
Prostate
26%
Antitumor Activity
25%
Ovarian Cancer Risk
24%
Thymopoietin
23%
Pancreatic Cancer
23%
LCS101
23%
Abiraterone Acetate
23%
Metastatic Disease
23%
Anticancer Effect
23%
Radiation Therapy
22%
Complete Response
21%
Patients with Cancer
19%
Personalized Medicine
19%
Patient Response
19%
Israeli
19%
Prostate Cancer Patients
19%
BRCA1, BRCA2
19%
Docetaxel
19%
Adverse Events
18%
Overall Survival of Patients
18%
Partial Response
18%
Castration-resistant Prostate Cancer
18%
Risk Factors
18%
Cancer Patients
18%
Botanical Drugs
17%
Stable Disease
17%
High Risk
17%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Disease
73%
Overall Survival
66%
Castration Resistant Prostate Cancer
63%
Chemotherapy
61%
Neoplasm
58%
Progression Free Survival
56%
Sunitinib
55%
Pembrolizumab
55%
Breast Cancer
44%
Kidney Metastasis
40%
Prostate Cancer
40%
Adverse Event
33%
Clinical Trial
31%
Transitional Cell Carcinoma
30%
Prostate Specific Membrane Antigen
27%
Biological Marker
26%
Abiraterone Acetate
23%
Renal Cell Carcinoma
23%
Solid Malignant Neoplasm
23%
Docetaxel
19%
Antitumor Activity
19%
Prostate Specific Antigen
17%
Metastasis
17%
Metastatic Colorectal Cancer
16%
Cabozantinib
15%
Somatomedin C Receptor
15%
Colorectal Carcinoma
15%
Triple Negative Breast Cancer
15%
Radioisotope
15%
Membrane Antigen
15%
Lutetium 177
15%
Receptor
15%
Recurrent Disease
15%
Retrospective Study
14%
Side Effect
12%
Disease Exacerbation
12%
Doxorubicin
11%
Biochemical Recurrence
11%
Immunotherapy
10%
microRNA
10%
Fluorouracil
10%
Reactive Oxygen Metabolite
10%
Colon Cancer
10%
Immune Checkpoint Inhibitor
10%
Insulin-Like Growth Factor 1
10%
Non Small Cell Lung Cancer
9%
Pharmacokinetics
9%
Liver Metastasis
9%
Phase II Trials
9%